Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 346

1.

Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.

Cies JJ, Shankar V, Schlichting C, Kuti JL.

Pediatr Infect Dis J. 2014 Feb;33(2):168-73. doi: 10.1097/INF.0b013e3182a743c7.

PMID:
23907263
2.

Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.

Cies JJ, Jain J, Kuti JL.

Pediatr Blood Cancer. 2015 Mar;62(3):477-82. doi: 10.1002/pbc.25287. Epub 2014 Oct 18.

PMID:
25328131
3.

Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.

Nichols K, Chung EK, Knoderer CA, Buenger LE, Healy DP, Dees J, Crumby AS, Kays MB.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):522-31. doi: 10.1128/AAC.02089-15.

4.

Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.

Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.

Ann Pharmacother. 2009 Nov;43(11):1747-54. doi: 10.1345/aph.1M304. Epub 2009 Oct 6.

PMID:
19809009
5.

Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.

Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.

Pharmacotherapy. 2014 Jan;34(1):28-35. doi: 10.1002/phar.1324. Epub 2013 Jul 17.

PMID:
23864417
6.

Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.

Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB.

J Clin Pharmacol. 2015 Aug;55(8):899-908. doi: 10.1002/jcph.505. Epub 2015 May 13.

PMID:
25823963
7.

Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.

Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.

J Antimicrob Chemother. 2014 Jan;69(1):176-9. doi: 10.1093/jac/dkt300. Epub 2013 Jul 18.

PMID:
23869050
8.

First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J.

Int J Antimicrob Agents. 2010 Feb;35(2):156-63. doi: 10.1016/j.ijantimicag.2009.10.008. Epub 2009 Dec 16.

PMID:
20018492
9.

Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.

Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.

J Antimicrob Chemother. 2014 Jan;69(1):180-9. doi: 10.1093/jac/dkt304. Epub 2013 Aug 1.

PMID:
23908259
10.

Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.

Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M.

Pharmacotherapy. 2015 Jun;35(6):600-7. doi: 10.1002/phar.1604.

PMID:
26095008
11.

Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

Patel N, Scheetz MH, Drusano GL, Lodise TP.

Antimicrob Agents Chemother. 2010 Jan;54(1):460-5. doi: 10.1128/AAC.00296-09. Epub 2009 Oct 26.

13.

Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.

Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB.

Int J Antimicrob Agents. 2013 Jan;41(1):52-6. doi: 10.1016/j.ijantimicag.2012.09.004. Epub 2012 Dec 8.

PMID:
23228881
14.

Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.

Kuti JL, Nightingale CH, Quintiliani R, Nicolau D.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):51-7.

PMID:
12376031
15.

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

Kim A, Sutherland CA, Kuti JL, Nicolau DP.

Pharmacotherapy. 2007 Nov;27(11):1490-7.

PMID:
17963458
16.

Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.

Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.

Pharmacotherapy. 2002 May;22(5):569-77.

PMID:
12013355
17.

Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.

Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB.

Int J Antimicrob Agents. 2009 Nov;34(5):429-33. doi: 10.1016/j.ijantimicag.2009.07.004. Epub 2009 Sep 1.

PMID:
19726163
18.

Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual.

Newman D, Scheetz MH, Adeyemi OA, Montevecchi M, Nicolau DP, Noskin GA, Postelnick MJ.

Ann Pharmacother. 2007 Oct;41(10):1734-9. Epub 2007 Aug 28.

PMID:
17726066
19.

Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.

Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y, Wu D, Zhu Y, Wang Y, Chen C.

Eur J Clin Pharmacol. 2013 Jun;69(6):1223-33. doi: 10.1007/s00228-012-1413-4. Epub 2013 Jan 26.

PMID:
23354809
20.

Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.

Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP.

Antimicrob Agents Chemother. 2012 Aug;56(8):4087-94. doi: 10.1128/AAC.00521-12. Epub 2012 May 14.

Supplemental Content

Support Center